Encephalopathy with rapid infusion ifosfamide/mesna. 1987

T J Perren, and R C Turner, and I E Smith

UI MeSH Term Description Entries
D007069 Ifosfamide Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent. Isofosfamide,Isophosphamide,Asta Z 4942,Holoxan,Iphosphamide,Iso-Endoxan,NSC-109,724,NSC-109724,Iso Endoxan,NSC 109,724,NSC 109724,NSC109,724,NSC109724
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008623 Mercaptoethanol A water-soluble thiol derived from hydrogen sulfide and ethanol. It is used as a reducing agent for disulfide bonds and to protect sulfhydryl groups from oxidation. 2-ME,2-Mercaptoethanol,2 Mercaptoethanol
D001927 Brain Diseases Pathologic conditions affecting the BRAIN, which is composed of the intracranial components of the CENTRAL NERVOUS SYSTEM. This includes (but is not limited to) the CEREBRAL CORTEX; intracranial white matter; BASAL GANGLIA; THALAMUS; HYPOTHALAMUS; BRAIN STEM; and CEREBELLUM. Intracranial Central Nervous System Disorders,Brain Disorders,CNS Disorders, Intracranial,Central Nervous System Disorders, Intracranial,Central Nervous System Intracranial Disorders,Encephalon Diseases,Encephalopathy,Intracranial CNS Disorders,Brain Disease,Brain Disorder,CNS Disorder, Intracranial,Encephalon Disease,Encephalopathies,Intracranial CNS Disorder
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015080 Mesna A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. 2-Mercaptoethanesulfonate,Coenzyme M,Ethanesulfonic acid, 2-mercapto-, monosodium salt,ASTA-D 7093,MESNA-cell,Mesnex,Mesnum,Mistabron,Mistabronco,Mitexan,Mucofluid,Sodium 2-Mercaptoethanesulphonate,UCB-3983,Uromitexan,Ziken,2 Mercaptoethanesulfonate,2-Mercaptoethanesulphonate, Sodium,ASTA D 7093,ASTAD 7093,MESNA cell,UCB 3983,UCB3983

Related Publications

T J Perren, and R C Turner, and I E Smith
April 1987, Lancet (London, England),
T J Perren, and R C Turner, and I E Smith
January 1989, Pediatric hematology and oncology,
T J Perren, and R C Turner, and I E Smith
August 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
T J Perren, and R C Turner, and I E Smith
August 1986, Lancet (London, England),
T J Perren, and R C Turner, and I E Smith
June 1985, Lancet (London, England),
T J Perren, and R C Turner, and I E Smith
August 1984, Lancet (London, England),
T J Perren, and R C Turner, and I E Smith
July 1986, European journal of cancer & clinical oncology,
T J Perren, and R C Turner, and I E Smith
April 1988, Presse medicale (Paris, France : 1983),
T J Perren, and R C Turner, and I E Smith
January 1996, Cancer investigation,
T J Perren, and R C Turner, and I E Smith
November 1989, The Medical letter on drugs and therapeutics,
Copied contents to your clipboard!